Calbindin-D 28kD immunofluorescence in ventral mesencephalic neurons labeled following injections of Fluoro-Gold in nucleus accumbens subterritories: inverse relationship relative to known neurotoxin vulnerabilities

Brain Research

Volumn 844, Issue 1-2, 1999, Pages 67-77

  Tan, Yun ^a   Williams, Evelyn S ^a   Zahm, Daniel S ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Calbindin D 28kD; Calretinin; Fluoro Gold; Nucleus accumbens; Tyrosine hydroxylase; Ventral tegmental area

Indexed keywords

CALBINDIN; CALCIUM BINDING PROTEIN; CALRETININ; FLUOROGOLD; MEMBRANE RECEPTOR; NEUROTOXIN; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; IMMUNOFLUORESCENCE; IMMUNOREACTIVITY; MALE; MESENCEPHALON; NEUROPROTECTION; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; VENTRAL TEGMENTUM;

ANIMALS; CALCIUM-BINDING PROTEIN, VITAMIN D-DEPENDENT; CELL SIZE; FLUORESCENT ANTIBODY TECHNIQUE; FLUORESCENT DYES; MALE; NEURONS; NEUROTOXINS; NUCLEUS ACCUMBENS; OXIDOPAMINE; RATS; RATS, SPRAGUE-DAWLEY; STILBAMIDINES; SYMPATHOLYTICS; TYROSINE 3-MONOOXYGENASE; VENTRAL TEGMENTAL AREA;

EID: 0032850930     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(99)01890-9     Document Type: Article

References (76)

1. Agid F.J., Agid Y. Is the mesocortical dopaminergic system involved in Parkinson disease? Neurology. 30:1980;1326-1330.
2. Arai R., Winsky L., Arai M., Jacobowitz D.M. Immunohistochemical localization of calretinin in the rat hindbrain. J. Comp. Neurol. 310:1991;21-44.
3. Baimbridge K.G., Celio M.R., Rogers J.H. Calcium-binding proteins in the nervous system. Trends Neurosci. 15:1992;303-308.
4. Bardo M.T., Hammer R.P. Jr. Autoradiographic localization of dopamine D1 and D2 receptors in rat nucleus accumbens: resistance to differential rearing conditions. Neuroscience. 45:1991;281-290.
5. Bennett B.D., Bolam J.P. Characterization of calretinin-immunoreactive structures in the striatum of the rat. Brain Res. 609:1993;137-148.
6. Broening H.W., Pu C., Vorhees C.V. Methamphetamine selectively damages dopaminergic innervation to the nucleus accumbens core while sparing the shell. Synapse. 27:1997;153-160.
7. Brog J.S., Salyapongse A., Deutch A.Y., Zahm D.S. The patterns of afferent innervation of the core and shell in the "accumbens" part of the rat ventral striatum: immunohistochemical detection of retrogradely transported Fluoro-Gold. J. Comp. Neurol. 338:1993;255-278.
8. Bubser M., Deutch A.Y. Thalamic paraventricular nucleus neurons collateralize to innervate the prefrontal cortex and nucleus accumbens. Brain Res. 787:1998;304-310.
9. Burrows K.B., Meshul C.K. Methamphetamine alters presynaptic glutamate immunoreactivity in the caudate nucleus and motor cortex. Synapse. 27:1997;133-144.
10. Celio M.R. Calbindin-D28k and parvalbumin in the rat nervous system. Neuroscience. 35:1990;375-475.
11. Churchill L., Dilts R.P., Kalivas P.W. Changes in gamma-aminobutyric acid, mu-opioid and neurotensin receptors in the accumbens-pallidal projection after discrete quinolinic acid lesions in the nucleus accumbens. Brain Res. 511:1990;41-54.
12. Churchill L., Kalivas P.W. Dopamine depletion produces augmented behavioral responses to a mu-, but not a delta-opioid receptor agonist in the nucleus accumbens: lack of a role for receptor upregulation. Synapse. 11:1992;47-57.
13. Cote P.Y., Sadikot A.F., Parent A. Complementary distribution of calbindin-D28K and parvalbumin in the basal forebrain and midbrain of the squirrel monkey. Eur. J. Neurosci. 3:1991;1316-1329.
14. Deutch A.Y., Cameron D.S. Pharmacological characterization of dopamine systems in the nucleus accumbens core and shell. Neuroscience. 46:1992;49-56.
15. Deutch A.Y., Lee M.C., Iadarolar M.J. Regionally specific effects of atypical antipsychotic drugs on striatal fos expression: the nucleus accumbens shell as a locus of antipsychotic action. Mol. Cell. Neurosci. 3:1992;332-341.
16. Geiser J.R., van Tuinen D., Brockerhoff S.E., Neff M.M., Davis T.N. Can calmodulin function without binding calcium? Cell. 65:1991;949-959.
17. Gerfen C.R., Baimbridge K.G., Miller J.J. The neostriatal mosaic: compartmental distribution of calcium-binding protein and parvalbumin in the basal ganglia of the rat and monkey. Proc. Natl. Acad. Sci. U.S.A. 82:1985;8780-8784.
18. Gerfen C.R., Baimbridge K.G., Thibault J. The neostriatal mosaic: III. Biochemical and developmental dissociation of patch-matrix mesostriatal systems. J. Neurosci. 7:1987;3935-3944.
19. Gerfen C.R. The neostriatal mosaic: multiple levels of compartmental organization. Trends Neurosci. 36:1992;43-59.
20. German D.C., Manaye K.F., Sonsalla P.K., Brooks B.A. Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced parkinsonism: sparing of calbindin-D28k-containing cells. Ann. N. Y. Acad. Sci. 648:1992;42-62.
21. German D.C., Liang C.L. Neuroactive peptides exist in the midbrain dopaminergic neurons that contain calbindin-D28k. NeuroReport. 4:1993;491-494.
22. Graybiel A.M., Moratalla R., Robertson H.A. Amphetamine and cocaine induce drug-specific activation of the c-fos gene in striosome-matrix compartments and limbic subdivisions of the striatum. Proc. Natl. Acad. Sci. U.S.A. 87:1990;6912-6916.
23. H.J. Groenewegen, G.E. Meredith, H.W. Berendse, P. Voorn, J.G. Wolters, The compartmental organization of the ventral striatum in the rat, in: A.R. Crossman, M.A, Sambrook (Eds.), Neural Mechanisms in Disorders of Movement, Libbey, London, 1989, pp. 45-54.
24. Haber S.N., Ryoo H., Cox C., Lu W. Subsets of midbrain dopaminergic neurons in monkeys are distinguished by different levels of mRNA for the dopamine transporter: comparison with the mRNA for the D2 receptor, tyrosine hydroxylase and calbindin immunoreactivity. J. Comp. Neurol. 362:1995;400-410.
25. Hammer R.P. Jr. Cocaine alters opiate receptor binding in critical brain reward regions. Synapse. 3:1989;55-60.
26. Heikkila R.E., Cohen G. Further studies on generation of hydrogen peroxide by 6-hydroxydopamine: potentiation by ascorbic acid. Mol. Pharmacol. 8:1972;241-248.
27. Heimer L., Zahm D.S., Churchill L., Kalivas P.W., Wohltmann C. Specificity in the projection patterns of accumbal core and shell in the rat. Neuroscience. 41:1991;89-125.
28. Heizmann C.W. Calcium signaling in the brain. Acta Neurobiologiae Experimentalis. 53:1993;15-23.
29. Herkenham M., Edley S.M., Stuart J. Cell clusters in the nucleus accumbens of the rat, and the mosaic relationship of opiate receptors, acetylcholinesterase and subcortical afferent terminations. Neuroscience. 11:1984;561-593.
30. Hirsch E.C., Mouatt A., Thomasset M., Javoy-Agid F., Agid Y., Graybiel A.M. Expression of calbindin D28k-like immunoreactivity in catecholaminergic cell groups of the human midbrain: normal distribution and distribution and distribution in Parkinson's disease. Neurodegeneration. 1:1992;83-93.
31. Horger B.A., Elsworth J.D., Roth R.H. Selective increase in dopamine utilization in the shell subdivision of the nucleus accumbens by the benzodiazepine inverse agonist FG7142. J. Neurochem. 65:1995;770-774.
32. Hussain Z., Johnson L.R., Totterdell S. A light and electron microscopic study of NADPH-diaphorase-, calretinin- and parvalbumin-containing neurons in the rat nucleus accumbens. J. Chem. Neuroanat. 10:1996;19-39.
33. Iacopino A., Christakos S., German D.C., Sonsalla P.K., Altar C.A. Calbindin-D28K-containing neurons in animal models of neurodegeneration: possible protection from excitotoxicity. Mol. Brain Res. 13:1992;251-261.
34. Isaacs K.R., Jacobowitz D.M. Mapping of the colocalization of calretinin and tyrosine hydroxylase in the rat substantia nigra and ventral tegmental area. Exp. Brain Res. 99:1994;34-42.
35. Isaacs K.R., de Erausquin G., Strauss K.I., Jacobowitz D.M., Hanbauer I. Differential effects of excitatory amino acids on mesencephalic neurons expressing either calretinin or tyrosine hydroxylase in primary cultures. Mol. Brain Res. 36:1996;114-126.
36. Johansen F.F., Tonder N., Zimmer J., Baimbridge K.G., Diemer N.H. Short-term changes of parvalbumin and calbindin immunoreactivity in the rat hippocampus following cerebral ischemia. Neurosci. Lett. 120:1990;171-174.
37. Jones S.R., O'Dell S.J., Marshall J.F., Wightman R.M. Functional and anatomical evidence for different dopamine dynamics in the core and shell of the nucleus accumbens in slices of rat brain. Synapse. 23:1996;224-231.
38. Jongen-Relo A.L., Voorn P., Groenewegen H.J. Immunohistochemical characterization of the shell and core territories of the nucleus accumbens in the rat. Eur. J. Neurosci. 6:1994;1255-1264.
39. Kalivas P.W., Duffy P. Selective activation of dopamine transmission in the shell of the nucleus accumbens by stress. Brain Res. 675:1995;325-328.
40. King D., Zigmond M.J., Finlay J.M. Effects of dopamine depletion in the medial prefrontal cortex on the stress-induced increase in extracellular dopamine in the nucleus accumbens core and shell. Neuroscience. 77:1997;141-153.
41. Koob G.F. Neural mechanisms of drug reinforcement. Ann. N. Y. Acad. Sci. 654:1992;171-191.
42. Liang C.L., Sinton C.M., German D.C. Midbrain dopaminergic neurons in the mouse: co-localization with calbindin-D28K and calretinin. Neuroscience. 75:1996;523-533.
43. McRitchie D.A., Hardman C.D., Halliday G.M. Cytoarchitectural distribution of calcium binding proteins in midbrain dopaminergic regions of rats and humans. J. Comp. Neurol. 364:1996;121-150.
44. Meredith G.E., Blank B., Groenewegen H.J. The distribution and compartmental organization of the cholinergic neurons in nucleus accumbens of the rat. Neuroscience. 31:1989;327-345.
45. Meredith G.E., Agolia R., Arts M.P., Groenewegen H.J., Zahm D.S. Morphological differences between projection neurons of the core and shell in the nucleus accumbens of the rat. Neuroscience. 50:1992;149-162.
46. Meredith G.E., Ypma P., Zahm D.S. Effects of dopamine depletion on the morphology of medium spiny neurons in the shell and core of the rat nucleus accumbens. J. Neurosci. 15:1995;3808-3820.
47. Möckel V., Fischer G. Vulnerability to excitotoxic stimuli of cultured rat hippocampal neurons containing the calcium-binding proteins calretinin and calbindin D28K. Brain Res. 648:1994;109-120.
48. Mouatt-Prigent A., Agid Y., Hirsch E.C. Does the calcium-binding protein calretinin protect dopaminergic neurons against degeneration in Parkinson's disease? Brain Res. 668:1994;62-70.
49. Nicotera P., Bellomo G., Orrenius S. Calcium-mediated mechanisms in chemically induced cell death. Annu. Rev. Pharmacol. Toxicol. 32:1992;449-470.
50. Nitsch C., Scotti A., Sommacal A., Kalt G. GABAergic hippocampal neurons resistant to ischemia-induced neuronal death contain the Ca2(+)-binding protein Parvalbumin. Neurosci. Lett. 105:1989;263-268.
51. Parmentier M., Lefort A. Structure of the human brain calcium-binding protein calretinin and its expression in bacteria. Eur. J. Biochem. 196:1991;79-85.
52. Persechini A., Moncrief N.D., Kretsinger R.H. The EF-hand family of calcium modulated proteins. Trends Neurosci. 12:1989;426-467.
53. Phillipson O.T., Golgi A. Study of the ventral tegmental area of Tsai and interfascicular nucleus in the rat. J. Comp. Neurol. 187:1979;99-115.
54. Pierce R.C., Kalivas P.W. Amphetamine produces sensitized increases in locomotion and extracellular dopamine preferentially in the nucleus accumbens shell of rats administered repeated cocaine. J. Pharmacol. Exp. Ther. 275:1995;1019-1029.
55. Pontieri F.E., Tanda G., Di Chiara G. Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the "shell" as compared with the "core" of the rat nucleus accumbens. Proc. Natl. Acad. Sci. U.S.A. 92:1995;12304-12308.
56. Resibois A., Rogers J.H. Calretinin in rat brain: an immunohistochemical study. Neuroscience. 46:1992;101-134.
57. Robbins T.W., Cador M., Taylor J.R., Everitt B.J. Limbic-striatal interactions in reward-related processes. Neurosci. Biobehav. Rev. 13:1989;155-162.
58. Robledo P., Maldonado-Lopez R., Koob G.F. Role of dopamine receptors in the nucleus accumbens in the rewarding properties of cocaine. Ann. N. Y. Acad. Sci. 654:1992;509-512.
59. Robledo P., Koob G.F. Two discrete nucleus accumbens projection areas differentially mediate cocaine self-administration in the rat. Behav. Brain Res. 55:1993;159-166.
60. Rogers J.H. Calretinin: a gene for a novel calcium binding protein expressed principally in neurons. J. Cell Biol. 105:1987;1343-1353.
61. Rogers J.H. Immunohistochemical markers in the rat brain: colocalization of calretinin and calbindin-D28k with tyrosine hydroxylase. Brain Res. 587:1992;203-210.
62. Sachs C., Jonsson G. Mechanism of action of 6-hydroxydopamine. Biochem. Pharmacol. 24:1975;1-8.
63. Sanghera M.K., Manaye K., McMahon A., Sonsalla P.K., German D.C. Dopamine transporter mRNA levels are high in midbrain neurons vulnerable to MPTP. NeuroReport. 8:1997;3327-3331.
64. Sloviter R.S. Calcium-binding protein (calbindin-D28k) and parvalbumin immunocytochemistry: localization in the rat hippocampus with specific reference to the selective vulnerability of hippocampal neurons to seizure activity. J. Comp. Neurol. 280:1989;183-196.
65. Sun C.J., Johannessen J.N., Gessner W., Bamura I., Singhaniyom W., Brossi A., Chiueh C.C. Neurotoxic damage to the nigrostriatal system in rats following intranigral administration of MPDP+ and MPP+. J. Neural Transm. 74:1988;75-86.
66. Swanson L.W. The projections of the ventral tegmental area and adjacent regions: a combined fluorescent retrograde tracer and immunofluorescence study in the rat. Brain Res. Bull. 9:1982;321-353.
67. Tan Y., Brog J.S., Williams E.S., Zahm D.S. Morphometric analysis of ventral mesencephalic neurons retrogradely labeled with Fluoro-Gold following injections in the shell, core and rostral pole of the rat nucleus accumbens. Brain Res. 589:1995;151-156.
68. Turner B.H., Wilson J.S., McKenzie J.C., Richtand N. MPTP produces a pattern of nigrostriatal degeneration, which coincides with the mosaic organization of the caudate nucleus. Brain Res. 473:1988;60-64.
69. Uhl G.R., Hedreen J.C., Price D.L. Parkinson's disease: loss of neurons from the ventral tegmental area contralateral to therapeutic surgical lesions. Neurology. 35:1985;1215-1218.
70. Voorn P., Gerfen C.R., Groenewegen H.J. Compartmental organization of the ventral striatum of the rat: immunohistochemical distribution of enkephalin, substance P, dopamine, and calcium binding protein. J. Comp. Neurol. 289:1989;189-201.
71. Winsky L., Nakata H., Martin B.M., Jacobowitz D.M. Isolation, partial amino acid sequence, and immunohistochemical localization of a brain-specific calcium binding protein. Proc. Natl. Acad. Sci. U.S.A. 86:1989;10139-10143.
72. Yamada T., McGeer P.L., Baimbridge K.G., McGeer E.G. Relative sparing in Parkinson's disease of substantia nigra dopamine neurons containing calbindin-D28K. Brain Res. 562:1990;303-307.
73. Zahm D.S. Compartments in rat dorsal and ventral striatum revealed following injection of 6-hydroxydopamine into the ventral mesencephalon. Brain Res. 552:1991;164-169.
74. Zahm D.S. An electron microscopic morphometric comparison of tyrosine hydroxylase immunoreactive innervation in the neostriatum and the nucleus accumbens core and shell. Brain Res. 575:1992;341-346.
75. Zahm D.S., Brog J.S. On the significance of subterritories in the "accumbens" part of the rat ventral striatum. Neuroscience. 50:1992;751-767.
76. Zahm D.S., Heimer L. Specificity in the efferent projections of the nucleus accumbens in the rat: comparison of the rostral pole projection patterns with those of the core and shell. J. Comp. Neurol. 327:1993;220-232.